Loading stock data…
BLLN
$100.36+7.40 (+7.96%)
Market OpenUpdated 2:35 PM EDT
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$100.36
Potential Downside
97%
Whystock Fair Value$2.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$114.86+14.4%
Range$90.00 – $145.00
Fundamentals
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.99B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
620.29
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.55%
Volume
Today's trading volume
692,192
Recent News
Discover May 2026's Top Stocks Estimated Below Intrinsic Value
Over the last 7 days, the United States market has risen by 3.2%, contributing to a remarkable 31% increase over the past year, with earnings projected to grow at an annual rate of 16%. In such a thriving market environment, identifying stocks that are estimated to be trading below their intrinsic value can present unique opportunities for investors seeking potential growth and value.
Wall Street Analysts Predict a 25.63% Upside in BillionToOne (BLLN): Here's What You Should Know
The mean of analysts' price targets for BillionToOne (BLLN) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BillionToOne, Inc. Q1 2026 Earnings Call Summary
Moby summary of BillionToOne, Inc.'s Q1 2026 earnings call
Billiontoone Q1 Earnings Call Highlights
Billiontoone (NASDAQ:BLLN) reported first-quarter 2026 results showing rapid revenue growth alongside GAAP profitability, driven by higher test volumes, rising average selling prices (ASPs), and expanding gross margins. Management also highlighted the launch of a new prenatal confirmation offering,
BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.